rgd peptide

RGD peptide (GRGDNP) (TFA) promote apoptosis through activation of conformation changes that enhance pro-caspase-3 activation and autoprocessing.

RGD peptide (GRGDNP) TFA functions as an inhibitor of integrin-ligand interactions, competitively blocking α5β1's interaction with the extracellular matrix (ECM). It induces apoptosis by triggering conformational changes that facilitate pro-caspase-3 activation and autoprocessing. Furthermore, RGD peptide (GRGDNP) TFA is critical in regulating cell adhesion, migration, growth, and differentiation [1] [2] [3].

RGD-Targeted Proapoptotic Peptide is a peptide that preferentially binds to integrins at sites of tumor angiogenesis through its C-terminal RGD-4C sequence (ACDCRGDCFC).

H-Gly-Arg-Gly-Asp-Asn-Pro-OH (GRGDNP) is a integrin-ligand interactions inhibitor.

CGGRGD acetate is a RGD derivative with cysteine as the n-terminal. CGGRGD was synthesized by solid phase peptide synthesis technology, and amino2-cyanobenzothiazole (2-cyanobenzothiazole) (2-cyanobenzothiazole (CBT) was added on the surface of PCL fiber

GRGDSP acetate(91037-75-1 free base) is a synthetic linear RGD peptide and is an integrin inhibitor.

LXW7 is an octamer disulfide cyclic peptide and αvβ3 integrin ligand, acts as a potent and specific endothelial progenitor cells (EPCs) and endothelial cells (ECs) targeting ligand. LXW7 is a disulfide cyclic octa-peptide (cGRGDdvc) containing unnatural amino acids flanking both sides of the main functional motif.

YRGDS Fibronectin Fragment acetate (YRGDS Fibronectin Fragment acetate (134282-68-1 free base))(134282-68-1 free base) is a fibronectin fragment acetate, an adhesion peptide that displays strong binding affinity to thrombin-stimulated platelets. It is RGD consisting of sequence.

Arg-Gly-Glu-Ser acetate is a RGD related peptide that is a control for the RGDS activity of fibrinogen binding to activated platelets.

Cyclo(RADfK) is a selective α(v)β(3) integrin ligand extensively used for research, therapy, and diagnosis of neoangiogenesis. It also serves as a negative control for cyclo(-RGDfK-), the RGD peptide, which modulates cell adhesion and is recognized by several integrin family members.

Cyclo(Gly-Arg-Gly-Asp-Ser-Pro) (c(GRGDSP)) is an RGD-containing inhibitory peptide and synthetic α5β1 integrin ligand that competitively inhibits the binding of invasin (Inv) to α5β1 integrin on Caco-2 cells [1].

GRGDSPK (EMD 56574) is an inhibitory peptide for RGD-mediated adhesion between integrin and extracellular matrix molecules.

Risuteganib is a synthetic RGD (arginyl-glycyl-aspartic acid)-class peptide that regulates the functions of multiple integrin isoforms.

This is a fibronectin fragment, an adhesion peptide that displays strong binding affinity to thrombin-stimulated platelets. It is RGD consisting of sequence.

RGD Trifluoroacetate is a tripeptide that effectively triggers cell adhesion, targets specific cell lines, and elicits particular cell responses by binding to integrins. It is the most effective and frequently used peptide sequence for stimulated cell adhesion on synthetic surfaces. Among the 24 integrins that bind to ECM molecules in an RGD-dependent manner are α3β1, α5β1, α8β1, αIIbβ3, αvβ1, αvβ3, αvβ5, αvβ6, αvβ8, and to some extent α2β1 and α4β1.

LXW7 TFA, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor with an anti-inflammatory effect. LXW7 has a high binding affinity to αvβ3 integrin (IC50: 0.68 μM). It increases the phosphorylation of VEGFR-2 and activation of ERK1/2.

G-{d-Arg}-GDSP, an RGD peptide analogue, binds to the adhesion receptor of integrins, inhibiting cellular attachment to fibronectin and osteoclast resorption [1].

Cyclo(Ala-Arg-Gly-Asp-Mamb) is a selective antagonist of the RGD peptide, with potential applications in pulmonary arterial hypertension research [1].

Arg-Gly-Glu-Ser (RGDS) is an RGD-related peptide used as a control for the activity of fibrinogen binding to activated platelets.

Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA (Cyclo RGDfC) TFA, a cyclic RGD peptide, displays a high affinity for αvβ3 integrin, effectively disrupting cell-integrin interactions. It suppresses pluripotent marker expression in embryonic stem cells (ESCs) and reduces the tumorigenic capability of mESCs in vivo, making it valuable in tumor research [1].

A20FMDV2, a peptide derived from the α-helical RGD cell-interacting domain of the VP1 capsid protein of foot-and-mouth disease virus (FMDV) serotype O, targets and binds αVβ6 integrin. It effectively disrupts αVβ6 integrin-mediated cell adhesion in H357 tongue squamous cell carcinoma cells that exhibit human αVβ6, with an inhibitory concentration (IC50) of 1.2 µM. Additionally, when labeled with 111indium-DTPA, A20FMDV2 (20 MBq) specifically attaches to αVβ6 integrin in a breast cancer mouse xenograft model using MCF10CA1a cells, facilitating targeted radiation imaging analysis.

GRGDSPK TFA (EMD 56574 TFA) is a peptide containing the Arg-Gly-Asp (RGD) sequence, serving as a competitive and reversible inhibitor of integrin-fibronectin binding. This compound is utilized in research to elucidate integrins' involvement in bone formation and resorption [1] [2].

Certepetide (CEND-1), also known as iRGD, is a bifunctional cyclic peptide that enhances tumor penetration. By interacting with alphav-integrins through its RGD motif and activating NRP-1, it transforms the solid tumor microenvironment into a temporary conduit for therapeutic agents. This property facilitates Certepetide's accumulation in tumors, making it a valuable tool in researching pancreatic cancer and other solid tumors [1] [2] [3].

Gly-Arg-Gly-Asp-Ser-Pro (GRGDSP) is used as a soluble integrin-blocking RGD-based peptide.

Arg-Gly-Glu-Ser TFA, an RGD-related peptide, serves as a control for evaluating the inhibitory activity of RGDS on fibrinogen binding to activated platelets.

RGD-4C, an arginine-glycine-aspartic acid peptide (ACDCRGDCFC), exhibits integrin binding activity. The primary integrin recognition site in extracellular matrix proteins, the Arg-Gly-Asp (RGD) sequence, allows peptides with this sequence to mimic matrix proteins' recognition specificity. As an αv-integrin ligand, RGD-4C can be conjugated with bioactive molecules to demonstrate antitumor effects in animal models [1] [2] [3].

CGGRGD is a RGD derivative with cysteine as the n-terminal. CGGRGD was synthesized by solid phase peptide synthesis technology, and amino2-cyanobenzothiazole (2-cyanobenzothiazole) (2-cyanobenzothiazole (CBT) was added on the surface of PCL fiber for ammo